Free Trial
→ Do this Before Elon’s Reveal on January 22nd (From Brownstone Research) (Ad)

Galecto Q2 2023 Earnings Report

Galecto logo
$5.78 +0.65 (+12.57%)
As of 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Galecto EPS Results

Actual EPS
-$10.25
Consensus EPS
-$15.00
Beat/Miss
Beat by +$4.75
One Year Ago EPS
N/A

Galecto Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galecto Announcement Details

Quarter
Q2 2023
Date
7/31/2023
Time
N/A

Conference Call Resources

Galecto Earnings Headlines

Galecto (NASDAQ:GLTO) Stock, Option Chain
November 15, 2024 | benzinga.com
Galecto, Inc. Announces Strategic Shift and Financial Overview
November 2, 2024 | markets.businessinsider.com
Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
January 21, 2025 | Brownstone Research (Ad)
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities
November 2, 2024 | tipranks.com
Galecto reports Q3 EPS ($3.39) vs ($7.50)
November 1, 2024 | msn.com
Galecto Reports Third Quarter 2024 Financial Results
November 1, 2024 | globenewswire.com
See More Galecto Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galecto? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galecto and other key companies, straight to your email.

About Galecto

Galecto (NASDAQ:GLTO), a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

View Galecto Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles